Gabapentin in late-onset poststroke seizures

Neurology. 2002 Dec 24;59(12):1991-3. doi: 10.1212/01.wnl.0000038388.57824.b6.

Abstract

Stroke is a frequent cause of epileptic seizures (ES) in adults. The authors evaluated the long-term efficacy and tolerability of gabapentin (900 to 1,800 mg/day) in 71 patients with a first poststroke late ES during a mean follow-up time of 30 months. ES recurred in 18.3% of the patients and side effects were noted in 27 cases (38%), but only two (2.8%) required discontinuation or early withdrawal. Gabapentin monotherapy was useful and safe for late poststroke ES.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetates / adverse effects
  • Acetates / therapeutic use*
  • Aged
  • Amines*
  • Anticonvulsants / adverse effects
  • Anticonvulsants / therapeutic use*
  • Cyclohexanecarboxylic Acids*
  • Dose-Response Relationship, Drug
  • Female
  • Follow-Up Studies
  • Gabapentin
  • Humans
  • Male
  • Middle Aged
  • Prospective Studies
  • Recurrence
  • Seizures / drug therapy*
  • Seizures / etiology*
  • Stroke / complications*
  • gamma-Aminobutyric Acid*

Substances

  • Acetates
  • Amines
  • Anticonvulsants
  • Cyclohexanecarboxylic Acids
  • gamma-Aminobutyric Acid
  • Gabapentin